Objective: Adenosine receptor activation has been implicated in the mechanism of ischaemic preconditioning protection. Evidence suggests adenosine A receptor involvement, and possibly A receptor involvement in the rabbit. This study investigated the roles of Human atrial trabeculae were superfused with oxygenated Tyrode's solution. After stabilisation, muscles underwent one of 8 protocols Ž . n s 6 per group , followed by 90 min of simulated ischaemia and 120 min of reoxygenation. The experimental endpoint was recovery of Ž . Ž . contractile function, presented as percentage baseline function. Results: 5 nM CPA 52.2 " 3.1% , 30 nM IBMECA 49.7 " 3.8% and Ž . preconditioning 55.3 " 2.5% produced similar functional recoveries at 120 min of reoxygenation; significantly different to controls Ž . Ž . Ž . 27.7 " 1.0%; P -0.05, ANOVA . When DPCPX 200 nM was added prior to 5 nM CPA, protection was lost 31.8 " 0.9% , but when Ž . added prior to 30 nM IBMECA, muscles continued to be significantly protected 41.5 " 2.3% . Conclusions: In human atrium both A 1 and A receptor stimulation appears to mimic ischaemic preconditioning. This may represent the first evidence for A receptor 3 3 involvement in 'pharmacological' preconditioning of human myocardium. q 1997 Elsevier Science B.V.
these receptors in human preconditioning. Human A -and A -selective compounds were chosen based on K values for inhibition of Ž . agonist were used alone and in combination with dipropylcyclopentylxanthine DPCPX a 62-fold selective A antagonist. Methods: 1 Human atrial trabeculae were superfused with oxygenated Tyrode's solution. After stabilisation, muscles underwent one of 8 protocols Ž . n s 6 per group , followed by 90 min of simulated ischaemia and 120 min of reoxygenation. The experimental endpoint was recovery of Ž . Ž . contractile function, presented as percentage baseline function. Results: 5 nM CPA 52.2 " 3.1% , 30 nM IBMECA 49.7 " 3.8% and Ž . preconditioning 55.3 " 2.5% produced similar functional recoveries at 120 min of reoxygenation; significantly different to controls Ž . Ž . Ž . 27.7 " 1.0%; P -0.05, ANOVA . When DPCPX 200 nM was added prior to 5 nM CPA, protection was lost 31.8 " 0.9% , but when Ž . added prior to 30 nM IBMECA, muscles continued to be significantly protected 41.5 " 2.3% . Conclusions: In human atrium both A 1 and A receptor stimulation appears to mimic ischaemic preconditioning. This may represent the first evidence for A receptor
Introduction
When the heart is subjected to brief periods of ischaemia and reperfusion it becomes resistant to infarction. This endogenous protective mechanism is termed w x 'ischaemic preconditioning' 1 , and it has been shown to w x occur in all animal species studied 2-6 .
The mechanisms by which ischaemic preconditioning may protect the heart have been partly characterised in both animals and in the human; these include the involvew x ment of adenosine A receptor activation 2 , protein ki-1 Ž . nase C activation PKC , and the possible opening of Ž . w x ATP-sensitive potassium K channels 7-9 .
ATP
Adenosine A receptor activation has been implicated 1 w x w x w x in the rabbit 10 , the dog 11,12 , and the pig 13 , but w x does not appear to be involved in the rat 14,15 . The activation of another adenosine receptor subtype, the A 3 receptor, has also been implicated in ischaemic precondiw x w x tioning in the rabbit [16] [17] [18] [19] and in the chick 20 . PKC involvement in ischaemic preconditioning has been alluded w x w x to in the rabbit 21 and the rat 22 , but there is also evidence for a possible interaction between PKC and the w x K channel in the rabbit 23 nant receptors have previously been used in the design of a w x similar study in rabbits 33 . To examine the role of A 1 receptors, the 194-fold selective A agonist, CPA, was 1 used alone and in combination with the 62-fold selective A antagonist, DPCPX. The role of A receptors was 1 3 similarly examined using the 10-fold selective A agonist, 3 IBMECA, such that any protection remaining in the presence of DPCPX could be attributed to activation of the A 3 receptor. w x receptors has previously been published 34 .
Methods

Recombinant human
Receptor particulate fraction preparation
Cells stably expressing either human A or human A 1 3 receptors were collected by centrifugation at 300 = g for 5 min, the supernatant was discarded and the cell pellet was Ž . resuspended in cell buffer consisting of mmolrl : HEPES Ž .
Ž . Ž . Ž . 10 , MgCl 5 , PMSF 0.1 , bacitracin 100 mgrml , 2 Ž . Ž . Ž leupeptin 10 mgrml , DNase I 100 mgrml , ADA 2 . Ž U r ml , pH 7.4. Crude cell membranes particulate frac-. tion were prepared by repeated aspiration through a 21-gauge needle, collected by centrifugation at 60 000 = g for 10 min and stored in cell buffer at y808C. 
2.1.4.
Atrial experimental design
Atrial trabeculae were derived from right atrial appendages harvested from patients undergoing cardiopul-Ž . monary bypass during coronary artery bypass graft CABG surgery for chronic stable angina. Patient exclusion criteria for this study included pre-existing arrhythmias, right ventricular failure, oral anti-arrhythmic or oral hypoglycaemic The transport and subsequent handling of the atrial specimens was conducted in an identical manner to that w x previously described 9 . The time interval between harvesting of the appendage and the start of superfusion was 20 min, during which time they were transported to the laboratory in preoxygenated Tyrode's solution. In brief, the trabeculae were dissected out, mounted and superfused w x in an organ bath and connected to a force transducer 9 .
Once the trabecula had been suspended in the organ bath, it was paced by field stimulation at 1 Hz. Platinum pacing electrodes were positioned in the organ bath on either side of the trabecula, and pacing was driven by an Ž . isolated stimulator Digitimer DS2, Hertfordshire, UK . The pulse width was fixed at 2 ms, and the pulse ampli-Ž . tude was set at twice threshold 30 V . The output of the Ž force transducer was recorded on paper Gould RS3400 . chart recorder, Ohio, USA .
At the end of the experiment, the width and length of the trabeculae were measured with an eyepiece graticule in Ž . an overhead microscope Prior, Cambridge, UK ; subsequently all specimens were weighed.
Simulated ischaemia
Simulated ischaemia was accomplished by superfusing the trabecula with substrate -free modified Tyrode's Ž . solution bubbled with 95% N r5% CO pH 7.24-7.34 2 2 to render it hypoxic, and rapid pacing at 3 Hz. In order to maintain constant osmolarity, whilst yielding a substratefree superfusate, 7.0 mM choline chloride was substituted for glucose and pyruvic acid. Reoxygenation consisted of re-exposure to oxygenated normal Tyrode's solution and pacing at 1 Hz, as for the stabilisation period.
Measured end points
The only end point that was taken was contractile Ž function force of contraction as a percentage of the base-. line which was measured at intervals throughout the experiment.
Materials
The adenosine A receptor agonist CPA was dissolved 1 Ž . in dimethylsulphoxide DMSO to give a stock solution which was stored at y708C. Aliquots of this stock solution were subsequently added to 100 ml of Tyrode's solution to give a final concentration of 5 nM.
The adenosine A receptor agonist IBMECA was dis-3 solved in DMSO to give a stock solution which was stored at y208C. Aliquots of this stock solution were subsequently added to 100 ml of Tyrode's solution to give final concentrations of 10 and 30 nM. The adenosine A receptor antagonist DPCPX was 1 dissolved in DMSO to give a stock solution which was stored at y708C. Aliquots of this stock solution were subsequently added to 100 ml of Tyrode's solution to give a final concentration of 200 nM. We did not perform control experiments with DMSO Ž . alone, as previous work by Speechly-Dick unpublished at this laboratory has shown that the amount of DMSO used as vehicle in these experiments had no independent protective or detrimental effect on human atrial tissue.
Experimental protocol
Following suspension in the organ bath, trabeculae were paced at 1-Hz unstretched for 15 min to allow time for recovery following transport and handling. They were then gradually stretched in a stepwise manner over approximately 15 min until the maximum force of contraction was achieved. Following a further 45-min period of stabilisation, the specimens were then randomised to one of eight Ž . groups Fig. 1 .
All groups eventually underwent a period of 90 min of simulated ischaemia followed by 120 min of reoxygena-Ž . tion. The control C group did not undergo any other treatment, whereas all other groups underwent treatment prior to the long simulated ischaemia: preconditioned group Ž . The baseline force of contraction was measured just prior to the start of any intervention and was assigned the arbitrary value of 100%. The force of contraction was then measured during preconditioning or drug exposure, just prior to the 90-min simulated ischaemia, at 15-min intervals during the simulated ischaemia, and at 30-min intervals during reoxygenation. For all these time points, the force of contraction is expressed as a percentage of the baseline force of contraction.
Statistics
All results were expressed as mean " s.e.m. Comparisons were made between groups through time using two-Ž . way analysis of variance ANOVA with repeated measures, and at individual time points using one-way analysis of variance with multiple comparisons. The Fisher's test ( ) Fig. 1 . Experimental protocols. All protocols were preceded by at least 45 min stabilisation. Eight groups were studied. All groups were subjected to 90 min of simulated ischaemia followed by 120 min of reperfusion. Preconditioning was induced by 3 min of simulated ischaemia and 7 min of reperfusion.
was used for multiple comparisons between the groups. A value of P F 0.05 was considered significant. 1 
Results
Human adenosine A and A K data
i
The K values of CPA, IBMECA and DPCPX for i inhibition of 125 I-ABA binding to human A and A 1 3 receptors are summarized in Table 1 . The adenosine receptor agonist, CPA, and adenosine receptor antagonist, DPCPX, were 194-and 62-fold selective for human A vs.
1
A receptors, respectively. The adenosine receptor agonist, 3 IBMECA, was 10-fold selective for A vs A receptors. 
Atrial trabeculae data
Samples were obtained from 37 patients with chronic Ž stable angina 30 men and 7 women; age range 42-80 years; median age 62 years; similar mean ages in each . group . No trabeculae were excluded in this study. If two suitable trabeculae could be dissected from one atrial appendage then each trabecula was allocated to one of Ž eight groups two sets of apparatus were used simultane-. ously .
The data show that there was no statistical difference in developed force between the eight groups at the end of the stabilisation period prior to entering the protocol, nor was there any difference in the length, width or weight of the Ž . atrial trabeculae used Table 2 .
Trabeculae controls and preconditioning data
Subjecting the control group to 90 min simulated ischaemia resulted in a dramatic reduction of the developed force which was evident within 15 min of the onset of the Ž . simulated ischaemia Fig. 2 . There was also a further reduction in the developed force over the ensuing 30 min of simulated ischaemia. In the control group, the force of contraction then plateaued until the onset of reoxygenation, during which there was a gradual, but small, increase in the force of contraction which reached a maximum of 27.7 " 1.0% of baseline. All other groups behaved in a similar fashion to the control group during the long period of simulated ischaemia.
Ischaemic preconditioning using simulated ischaemia and reoxygenation resulted in a significant and immediate reduction in the measured force of contraction initially Ž . Fig. 2 . In this group, at the end of the preconditioning Ž stimulus, the force of contraction was 32.3 " 4.5% P -. 0.05 vs. all other groups . However, the developed force of contraction underwent a dramatic recovery during the short reoxygenation phase of the preconditioning protocol to Ž 96.8 " 2.0% not significantly different to the other . groups . Subsequent recovery of function during reoxygenation was significantly different to that of controls, in that at the end of the 120 min of reoxygenation contractile Ž . force was 55.3 " 2.5% P -0.05 vs. control .
A -mediated preconditioning 1
Ž . Prior treatment with CPA 52.2 " 3.1% resulted in a significant improvement in the force of contraction when Ž . compared to the control group Fig. 2 . The DPCPX Ž . 28.7 " 1.2% on its own showed no protection and be-Ž haved in a similar manner to the control group 27.7 "
. Ž . 1.0% Fig. 2 . The protection afforded by CPA was completely abolished by the addition of DPCPX, the spe-Ž cific A receptor antagonist, CPA q DPCPX 31.8 " 0.9% 1 . Ž . vs. CPA 52.2 " 3.1%; P -0.05 Fig. 2 . 
A -mediated preconditioning 3
Ž . Prior treatment with 30 nM IBMECA 49.7 " 3.8% resulted in a significant improvement in the force of Ž . contraction when compared to the control group Fig. 3 . Ž . The 10 nM IBMECA group 34.0 " 3.3% showed no ( )protection and behaved in a similar manner to the control Ž . group 27.7 " 1.0% . The protection afforded by 30 nM IBMECA was only partially abolished by the addition of DPCPX, with the resulting protection still significantly Ž better than controls 30 nM IBMECAq DPCPX 41.5 " 2.3%, 30 nM IBMECA 49.7 " 3.8% vs. control 27.7 "
. Ž . 1.0%; P -0.05 Fig. 3 . 
Discussion
One of the possible theories of ischaemic preconditioning protection is the stimulation of the adenosine A 1 receptor. Although stimulation of the A receptor has been 1 shown to play a role in human ischaemic preconditioning w x 30 , involvement of the adenosine A receptor remains 3 undefined. In this study we have attempted to establish a link between A receptor stimulation and human is-3 chaemic preconditioning protection.
In this study, pretreatment of the trabeculae with CPA resulted in protection which was comparable to that of ischaemic preconditioning. The 5 nM CPA dose was chosen to be the one antagonised by DPCPX, as it provided protection while maintaining A selectivity; the addition of 1 DPCPX abolished the protective effects of CPA. These results provide convincing evidence that CPA brought about its protection through stimulation of the adenosine A receptor. 1 IBMECA, a moderately selective adenosine A agonist, 3 produced no measurable protection at 10 nM; but at 30 nM, it resulted in protection which was comparable to that of both treatment with CPA, and preconditioning. We attempted to dissociate the effects of adenosine A recep- . pyl-adenosine R-PIA , was used, with a similar degree of protection to that seen with preconditioning. Also the non-selective adenosine antagonist 8-p-sulphophenyltheo-Ž . phylline SPT abolished the protective effect of precondiw x tioning without adversely affecting controls 30 .
It is interesting to note that although investigators agree on the possible involvement of the adenosine A receptor 1 w x stimulation in the rabbit heart 16 , there remains a degree of controversy on whether ischaemic preconditioning is w x mediated via this receptor in the rat 15,25,36 . There is also evidence that ischaemic preconditioning involves the w x adenosine A receptor subtype in the rabbit heart 37 . Despite the original definition of ischaemic precondiw x tioning relating to infarct size limitation 1 , improved myocardial contractile function appears dependent on infarct size limitation, rather than an anti-stunning effect w x 41,42 . In this isolated trabecula model, it is possible that cell death may occur following 90 min of simulated ischaemia. It has been shown to be a reliable model producing consistent results using both animal and human tissues w x 9,30,43 .
The data in this study suggest a potentially important role for adenosine A receptor stimulation in human phar-3 ( )macological preconditioning. Further studies in this field are required in order to establish the relevance of adenosine A stimulation to ischaemic protection of human 3 myocardium, especially the left ventricle. Defining which specific adenosine receptor subtype brings about ischaemic protection may lead to the development of novel cardioprotective agents.
